Wesana Health Holdings Inc. announced that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration, the Company is exploring the opportunity to expand its lead indication for SANA-013 to Major Depressive Disorder following the completion by the Company of a non-brokered private placement. Consistent with the positive feedback received from the FDA, Wesana is also exploring the opportunity to accelerate the development of SANA-013 by initiating a Phase 1b/2a human study for MDD in the first half of 2023. In contrast to the current development pathway for SANA-013 with TBI associated anxiety as the lead indication, currently targeting the launch of a Phase 1 study in Fourth Quarter of 2022 in a healthy human patient population, the revised development pathway would allow the Company to bypass the healthy patient population study and research an MDD affected patient population directly as part of a Phase 1b/2a study. MDD is a chronic, recurring, and debilitating mental disorder leading it to be one of the most burdensome illnesses on a global scale. Patients suffering from MDD are frequently and significantly impaired from an occupational and social function standpoint resulting in severe economic costs.